[Improved prognosis of fetal erythroblastosis through the variation of prophylactic and therapeutic measures].
D000136:Acid-Base Equilibrium; D001787:Blood Group Incompatibility; D001793:Blood Preservation; D001803:Blood Transfusion; D004899:Erythroblastosis, Fetal / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D005260:Female; D006493:Heparin; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007136:Immunoglobulins / Q000627:therapeutic use; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011379:Prognosis; D012204:Rh-Hr Blood-Group System / Q000037:antagonists & inhibitors
D007074:Immunoglobulin G; D007136:Immunoglobulins; D012204:Rh-Hr Blood-Group System; D006493:Heparin
Die Verbesserung der Prognose der hämolytischen Fetose durch Veränderung prophylakticher und therapeutischer Massnahmen.